An analysis of 2 pharmacovigilance databases revealed a high prevalence of azacitidine-related adverse events in patients with MDS or AML.

Cancer patients may have an increased risk of developing second primary malignancies after immune checkpoint inhibitor therapy.

Study results suggest that “telemedicine represents a unique opportunity to reduce time and travel burdens for patients with cancer considering clinical trials,” according to researchers.

Luveltamab tazevibulin demonstrated activity in an ongoing phase 2/3 trial of patients with FRα-positive, platinum-resistant ovarian cancer.